In conclusion, our study revealed that serum miR-222-3p is the potential factor to predict pCR, survival benefit and trastuzumab-induced cardiotoxicity for HER2-positive breast cancer patients receiving NAT. This evidence concerns the gene ERBB2 and breast cancer.